Drug intelligence / Profile preview

Keqing capsule

Development stage: Phase 4
Lead developer: 贵州百灵企业集团和仁堂药业
Administration: Oral

Overview

**Keqing capsule** is an oral Chinese herbal medicine product containing *Reineckea carnea*, opium poppy hull, *Ardisia japonica*, *Saxifraga stolonifera*, loquat leaf, and white mulberry root bark. It is marketed in China for cough associated with the common cold and chronic bronchitis, with traditional stated actions of moistening the lung, relieving asthma, suppressing cough, and promoting expectoration. Its approved labeling does not define a validated molecular target or pharmacologic mechanism. A randomized, open-label, controlled Chinese trial registered in 2020 evaluated Keqing capsule together with Kesuting syrup for mild and moderate COVID-19; this registration does not establish clinical efficacy for COVID-19. ([chictr.org.cn](https://www.chictr.org.cn/showproj.html?proj=49666))

Brand names: 百灵鸟联盛
Other names: Ke Qing Jiao NangKeqing咳清胶囊

Beyond the preview

Go deeper on Keqing capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Keqing capsule.